Novel therapy opportunities such as tyrosine-kinase inhibitors targeting BCR::ABL1, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, antibody–drug conjugates (inotuzumab-ozogamicin), monoclonal antibodies (rituximab) and bispecific antibodies (blinatumomab) have significantly improved the treatment options for adults with ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.